Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®).
Marcelien H E CallenbachDaphne SchoenmakersRick A VremanSylvia VijgenLonneke TimmersCarla E M HollakAukje K Mantel-TeeuwisseWim G GoettschPublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
Outcome-based models can mitigate the financial risk of reimbursing atidarsagene autotemcel. This can be considerably beneficial over simple discounts when clinical performance was similar to or worse than predicted.